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Type 2 diabetes or non-diabetic patients (50.3 years, vs. 69.5 and 66.6 years respec-
tively) at the time of surgery. The average cost of diabetic patients (both types) was 
more than twice the cost of non-diabetics in both glaucoma surgery (€ 7,972 vs. 
€ 3,278; p< 0.001) and cataract extractions (€ 10,668 vs. € 3,935; p= 0.031) and about 
30% higher in vitrectomies (€ 3,755 vs. € 2,869; p< 0.001). LOS was also systematically 
higher in diabetic patients (glaucoma surgery: 5.8 vs. 2.4 days; vitrectomy: 2.3 vs. 1.7 
days; cataract extraction: 14.7 vs. 3.0 days). ConClusions: The presence of diabetes 
increases dramatically both LOS and hospitalization costs in patients undergoing 
ophthalmological surgery.
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objeCtives: To estimate annual productivity loss costs attributable to having obe-
sity in working US adults with diabetes. Methods: This study applied a cross-
sectional design using the 2003-2012 Medical Expenditure Panel Survey (MEPS) data. 
Asthma patients (18-64 years old) were self-reported, had a Clinical Classification 
Codes of 0049, 050, or ICD-9-CM code of 250. To investigate the impact of having 
obesity, patients were classified as normal-weight (18.5≤ BMI< 25), overweight (25≤ 
BMI< 30), and obese (BMI≥ 30). Productivity loss costs, which were measured based 
on missed work days due to illness or injury for one year and the hourly wage, were 
estimated using a two-part model to adjust for patients with zero costs. To estimate 
the productivity loss costs attributable to having obesity, each group of costs was 
estimated by assuming everybody to be obese; these costs were then re-estimated by 
assuming everybody was normal weight, and the mean difference between the two 
estimated costs was calculated. All costs were converted to 2013 US dollars using 
the Consumer Price Index. Results: Among a total of 6,992 working adults with 
diabetes, the prevalence of normal-weight was 12.9%, overweight 30.1%, and obese 
57.0%. Annual average productivity loss costs for normal-weight and obesity in dia-
betes patients were $471(95%CI:$354-$588) and $585(95%CI:$523-$647) per patient, 
respectively. Among patients with diabetes who had loss of productivity costs, those 
with obesity had 1.02 times greater productivity loss costs than normal-weight 
patients after adjusting for patients’ demographic and clinical characteristics. The 
adjusted productivity loss costs attributable to having obesity in working diabetes 
patients was estimated at $77(95%CI:$76-$78) per patient per year. ConClusions: 
The loss of productivity costs among US diabetes patients is substantial, which is 
amplified by the presence of obesity. This study highlights the importance of obesity 
control in order to reduce costs and enhance productivity in patients with diabetes.
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objeCtives: Changes in healthcare resource utilization by Type 2 diabetes (T2D) 
patients over time are important for understanding the effects that treatment 
paradigms may have on costs of disease. This study was a longitudinal assessment 
of real-world claims data which followed changes in treatment costs for a single 
cohort (N= 35017) of newly diagnosed T2D patients. Methods: The Truven Health 
MarketScan® Database was examined for claims data from US-based T2D patients. 
Inclusion criteria were: at least 2 diagnoses according to ICD-9 codes for T2D, or 1 
T2D diagnosis plus 1 or more OAD claims, and allowing 1 possible misdiagnosis for 
type 1 diabetes, ≥ 18 years of age, continuous enrolment starting from 2006 (index 
year) to 2012 in a plan with prescription benefits, and at least 1 prescription for any 
anti-diabetic drug . All-cause costs of inpatient and outpatient services, medications, 
and supplies were analyzed. Results: From 2006-2012, total annual costs/patient 
increased from $9,817 to $12,551, adjusted to 2012 levels. Costs for outpatient ser-
vices grew 33% ($4,214-$5,645/outpatient). Outpatient emergency room utilizer costs 
rose 40% ($1,846-$2,586/utilizer). Total inpatient costs rose 47% ($19,453-$28,526), 
followed by a 36% growth of inpatient emergency room costs ($15,823-$21,526). 
Inpatient costs/1-day stay rose from $3,473 to $4,322, and inpatient ER costs/1-day 
stay increased from $2,776-$3,261. From 2006-2012, mean total days/stay/inpatient 
remained stable between 5.6 to 6.0 days, indicating annually increasing costs for 
inpatient services. Overall annual drug costs/utilizer increased 14% ($2,969-$3,389), 
as did anti-diabetic drug costs/utilizer (81%; $474-$858). Between 2006-2012, diag-
nosed T2D-assocated comorbidities increased as follows: cerebrovascular disease 
(13%-21%), peripheral vascular (3%-10%), nephropathy (3%-13%), and retinopathy 
(4%-14%). ConClusions: Costs for all types of resource utilization increased, rang-
ing from 17% to 81%, mainly driven by increased inpatient costs. Population aging 
may partly be responsible for the increased comorbidities, thus accounting for some 
increased treatment costs, along with increased drug costs.
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objeCtives: The SGLT2 inhibitor dapagliflozin (DAPA) increases glucosuria in an 
insulin-independent manner resulting in reductions in hyperglycemia, weight 
and BP with a low risk of hypoglycemia. Glipizide (GLIP) reduces hyperglycemia by 
increasing beta cell insulin secretion with risk of hypoglycaemia and weight gain. 
We conducted a cost analysis of treating patients over 4 years to two relevant com-
posite endpoints: (1) HbA1c lowering of ≤ 0.5%, no major or minor hypoglycaemic 
events and weight loss ≥ 3% and (2) HbA1c lowering of ≤ 0.5%, no major or minor 
hypoglycaemic events and weight loss ≥ 5%. Methods: The Cardiff Diabetes model 
41 841 (~EUR 1 518) per one patient. The total average cost per one type-2-diabetes 
patient was CZK 55 956 (~EUR 2.031) in 2014. ConClusions: Our data indicate that 
the cost of type 2 diabetes mellitus was CZK 55 956 (~EUR 2 031). A longitudinal study 
is, however, required to confirm the development of the average patient cost and 
take account of the cost of complications.
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objeCtives: diabetic foot syndrome (DFS) is expensive complication of diabetes 
leading to disability. There are costly innovative drugs that can make complications 
more curable. It is necessary to obtain evidences of new technologies economic ben-
efits. The aim of the study was to determine the economic burden of DFS in health 
care of the Republic of Belarus. Methods: “cost of illness” analysis for outpatient 
and inpatient treatment of DFS patients has been performed. A retrospective study 
of treatment of 15 outpatients with diabetic ulcers and 16 inpatients who under-
went amputation of different levels has been made. Direct and indirect costs were 
estimated. Average, minimal, maximal costs were calculated. All costs are given in 
euros (may, 2015). Results: out-patient direct medical costs are 259 (78 to 636) per 
patient/year. Indirect costs are 1941 (from 1022 to 4357) per patient/year. The cost 
of “big” amputation is 5248 (from 647 to 13,556) per hospitalization and 1099 (from 
282 to 3702 euros) for “small” amputations. Indirect costs range from 352 to 978 
during the period of treatment. ConClusions: Amputation usually considered 
as emergency aid in the case of DFS makes significant financial burden for hospi-
tals and health care system. Careful assesment of cost of illness of diabetes and 
it’s complications allows to expand opportunities of expansive outpatient medical 
technologies use.
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objeCtives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study 
aims to describe characteristics of patients with type 2 diabetes and patterns of 
use of antihyperglycemic agents in France in 2013. Methods: A random sample 
of ≈ 600,000 patients registered in the French national health insurances reim-
bursement database was used. Patients with diabetes were identified through 
their use of glucose-lowering medication and coding of hospital stays and long-
standing condition insurance coverage in the database. Drug utilization pattern 
of antihyperglycemic agents were estimated considering prescriptions in Q4 2013 
and compared to data from Q4 2007. Results: Overall 28,708 patients with T2D 
(estimated database prevalence 4.5%, 8.8% in people aged 40 and over) were iden-
tified in 2013. Mean age was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D 
pharmacologically treated patients received a monotherapy, 25.6% a dual therapy, 
13.7% a multi-therapy and 19.5% an insulin therapy with or without other hypo-
glycemic agents. Compared to 2007 data, a slight but significant increasing trend 
toward combination therapies and insulin was observed. The use of metformin 
increased over time especially in monotherapy (66% among monotherapy in 2013 
versus 50% in 2007). All thiazolidinediones and some sulfonylureas treatments 
were replaced by DPP-4 inhibitors and to a much lesser extent with GLP-1 ana-
logues. ConClusions: Antihyperglycemic prescription patterns in France have 
changed in recent years in parallel with the introduction of different classes 
of medications to the marketplace but probably also in an attempt to improve 
glycemic control of patients. Knowledge of real life pattern of drug utilization 
remains an important dimension to better understand therapeutic needs in T2D 
management.
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objeCtives: Ophthalmological complications (glaucoma, retinopathy, cataract) are 
frequent in patients with type I or type II diabetes and often require surgical treat-
ment. This study aimed at assessing the impact of diabetes on the hospitalization 
costs and the length of stay associated with these surgical treatments in Belgium, 
using retrospective data. Methods: The average hospitalization cost and the aver-
age length of stay (LOS) among patients hospitalized for ophthalmological surgery 
were estimated using the longitudinal IMS Hospital Disease Database (year 2013), 
including data (diagnoses, procedures, costs) on 24% of Belgian hospital beds. Stays 
were searched based on ICD-9-CM procedure codes corresponding to surgery for 
glaucoma (12.1 to 12.7), vitrectomy (14.71-14.74) and cataract extraction (13.19, 13.6). 
Patients were identified as diabetic if at least one diagnostic of diabetes (ICD-9-CM: 
249-250) had been documented during the calendar year. The impact of diabetes on 
LOS/ cost was assessed through Wilcoxon non-parametrical tests. Results: 671 
stays with surgery for glaucoma, 1,438 stays with vitrectomy and 204 stays with 
cataract extraction were retrieved in the database (with diabetic patients accounting 
for 56, 202 and 24 of these stays respectively). Patients with Type I diabetes (n= 16, 
split between glaucoma surgery and vitrectomy) were significantly younger than 
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insured urban population in China. Methods: A pooled cross-sectional analy-
sis was performed using China Health Insurance Research Association Database 
of year 2010, 2011 and 2012. Hospitalizations with T2D were identified using 
ICD-10 codes. Adult patients without any cancer or ketoacidosis were included. 
Descriptive statistics were used to analyze hospitalization costs and medication 
usage in T2D patients by age group cut at 60. Results: A total of 11,157 T2D hos-
pitalization records from 13 cities were analyzed, with 56.77% are elderly patients, 
and 32% of total patients have at least one comorbidity. The mean length of stay 
(LOS) per admission was 16 days in elderly patients, and 14 days in patients under 
60. The average direct cost per hospitalization and reimbursement ratio in elderly 
patients were ¥9,036.74 (±7675.74) and 77.34%, compared to ¥8084.34 (±5304.76) 
and 72.11% in patients under 60, respectively. On average, LOS was found 1 day 
longer, and hospitalization costs were found ¥1120 higher in T2D patients with 
comorbidities compared to those without. The average number of medications 
used per admission was 13 and 11 in patients ≧ 60 and under 60, respectively. 
In T2D elderly patients, majority (68.92%) used combination of oral antidiabetic 
drugs (OAD) and insulin. Acarbose and metformin were the most 2 frequently 
used OAD in all treatment choices. For non-antidiabetic medications, the most 
two frequently used drugs were aspirin and mecobalamine. ConClusions: Direct 
medical cost is considerable in elderly T2D patients under hospitalization, espe-
cially in those with comorbidities. The study also showed a complex medication 
usage pattern in elderly population.
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objeCtives: Chronic Kidney Disease (CKD) is a common comorbidity of Type 
2 Diabetes (T2D). This study is to explore the direct cost and medication usage 
pattern in T2D with CKD inpatients among insured urban population in Beijing 
and Tianjin, China. Methods: A pooled cross-sectional analysis was performed 
using hospitalization records in Beijing and Tianjin from China Health Insurance 
Research Association Database of year 2010, 2011 and 2012. Hospitalizations with 
T2D and CKD were identified using ICD-10 codes. Adult patients without any 
cancer or ketoacidosis were included. Descriptive statistics were used to analyze 
hospitalization costs and medication usage. Results: A total of 810 T2D with 
CKD hospitalizations were identified, accounting for 20.1% of the total T2D hospi-
talizations. The mean age (±SD) showed on the records were 62.42 (±11.78) years, 
with 16.15±8.92 days length of stay. The direct cost per admission was 10,155.68 
(±7,614.79), with 77.5% reimbursed by basic medical insurance. Medication cost 
accounted for 47.55% of the total cost, among which 29.57% were antidiabet-
ics. Averaged 15+ drugs were prescribed per admission. For T2D treatment 
choices, 13.33% patients used oral antidiabetic drugs (OAD) alone, and 66.75% 
used OAD and insulin combination. Acarbose and metformin were the two most 
frequently used OADs in all treatment choices. For non-T2D related medication 
treatment in T2D with CKD patients, aspirin and nifedipine were the two most 
frequently used drugs. Drugs on renin-angiotensin system (RAS) were the 5thfre-
quently used non-antidiabetics. ConClusions: Managing T2D among patients 
with CKD could be challenging given the renal impairment. This study showed 
that the direct cost in T2D patients with CKD per hospitalization was consid-
erable and their medicine usage pattern was complex in Beijing and Tianjin in 
China. More attention should be paid to the rational use of medication in such 
population.
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objeCtives: To quantify the association between weight change, diabetes-
related healthcare costs, and HbA1c among patients with type 2 diabetes (T2D); 
analyses were also conducted in sub-group of obese patients with no prior car-
diovascular disease. Methods: This retrospective, observational cohort study 
used U.S. insurance claims linked to laboratory and electronic medical records. 
Study included patients with T2D who were age≥ 18 years and added/switched to 
a non-metformin antidiabetes medication after metformin monotherapy between 
Jan-1-2007-Jun-30-2012 (add/switch date= index). Primary predictor was percent-
age weight change (PWC) between weight measurement at index and follow-up 
measurement 6 months thereafter ranging from negative (loss) to positive (gain). 
Outcomes, measured in 12-month period beginning at follow-up weight meas-
urement, included HbA1c< 7 and diabetes-related healthcare costs. Multivariable 
models quantified the association between PWC (linear effect) and study out-
comes. Results: Primary analysis included 1,520 patients (mean age 55 years; 
47% female); sub-group analysis included 780 patients (mean age 53 years; 51% 
female). Mean (SD) index weight and PWC were 224.6 (52.8) lbs and +0.2% (4.7%) in 
primary analysis; 241.3 (47.3) lbs and -0.2% (4.6%) in sub-group analysis. Negative 
PWC values were significantly associated with higher adjusted probabilities of 
achieving HbA1c< 7 (primary analysis: 58.8 % for PWC of -5% vs. 46.7% for PWC 
of +5%, P< 0.001; sub-group 63.2% for PWC -5% vs. 41.7% for PWC .5%, P< 0.001). 
Increasing PWC was significantly associated with increasing diabetes-specific 
pharmacy costs (P< 0.001) in primary analysis sample and with increasing all-
cause pharmacy costs (P= 0.018), diabetes-specific total costs (P= 0.039), diabetes-
specific medical costs (P= 0.002), and diabetes-specific pharmacy costs (P< 0.001) 
in sub-group sample. PWC was not significantly associated with all-cause total 
was used to estimate the cost of treating T2DM patients to two composite endpoints 
in a UK setting, using 208 week data from a previously published double-blind 
randomised clinical trial of dapagliflozin (DAPA) vs glipizide (GLIP) (NCT00660907). 
Calculation of costs included drug acquisition costs, cost for adverse events, micro- 
and macrovascular complications, and BMI related costs The cost of treating one 
patient to the composite endpoints using DAPA+MET versus GLIP+MET over 208 
weeks was calculated as total cost per treatment arm divided by number of patients 
that reached the composite endpoint in each arm. Results: The number needed 
to treat was 4 for DAPA+MET and 35 for GLIP+MET and overall cost of treating 
one patient over 208 weeks to composite endpoint (1) was £12,042 for DAPA+MET 
and £50,040 for GLIP+MET. The corresponding figures for composite endpoint (2) 
was 4 for DAPA+MET and 47 for GLIP+MET with corresponding costs of £12,666 
and £59,366. ConClusions: The cost of treating one patient to the composite 
endpoints was approximately 4.1-4.7 times higher with GLIP+MET compared to 
DAPA+MET. These results demonstrate that when multiple treatment goals, 
including weight loss and reduction of hypoglycaemic events are targeted, the cost 
of treating patients with DAPA+MET is lower compared to GLIP+MET.
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objeCtives: To correlate spending on diabetes drug prescriptions in English gen-
eral practices with occurrence of risks associated with type 2 diabetes. Methods: 
Data from the HSCIC showing number of prescriptions, by drug, issued in English 
general practices in 2014 and the associated net ingredient cost (NIC) were ana-
lysed using a proprietary in-house software. The total number of patients per CCG 
with diagnosed diabetes, stroke and ischemia, peripheral atrial disease, hyper-
tension, heart failure, coronary heart disease and atrial fibrillation between April 
2013 and March 2014 were identified through the HSCIC’s QOF data. The median 
age in a CCG was identified using ONS 2012 data. Spearman’s correlations and 
partial correlations were performed using SPSS v22.0. ‘Spend’ was defined as 
total NIC. Results: As expected, spending on prescriptions for diabetes drugs 
correlated almost perfectly with the number of diabetes patients (r= 0.97***). All 
the included risks associated with diabetes, bar age, correlated significantly with 
spending on diabetes prescriptions. The highest correlation was with the number 
of patients with obesity (r= 0.92***). The most expensive type of diabetes drugs were 
insulins. The correlations between spend on insulin prescriptions and number 
of patients with each individual diabetes risk was always higher than the cor-
relations between spend on prescriptions for all diabetes drugs and number of 
patients with each individual associated risk. The same was true when correlating 
the total number of prescriptions with occurrence of diabetes associated risks. 
Interestingly, both of these trends remained true when controlling for number of 
patients diagnosed with diabetes using partial correlations. ConClusions: As 
the occurrence of risks associated with diabetes increase, the spend on diabetes 
prescriptions is likely to increase. This is not only because more prescriptions 
are issued but also because the likelihood of insulins, the most expensive type of 
diabetes drugs, being prescribed increases.
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objeCtives: To examine the longitudinal effects and key costs of medication non 
adherence in patients with diabetes mellitus. Methods: The prospective study 
was conducted over a period of six months in a South Indian Village. Adherence to 
treatment has been assessed during a personal interview with each patient by using 
questionnaire. Medication adherence was assessed by using Morisky medication 
adherence scale (MMAS). Results: A total of 658 patients were diagnosed with 
Type 2 diabetes mellitus among them 87% (n= 572) of the patients were prescribed 
with oral hypoglycemic agents for more than a year were selected as study popula-
tion. The statistical significant association with socio demographic and adherence 
rate to antidiabetic therapy indicated that higher prevalence of adherence among 
uneducated (41.22%) elderly (32.82%) women (42.26%) unemployed (29.95%). The 
most common causes for nonadherence to taking medications were lack of knowl-
edge (35.25%) unaffordability () experience of untoward reactions (15.62%). Feeling 
better (26.5%). The adherence levels were 35 %( poor adherence), 27% (medium), 
and 38% (high). Among the poor adherence, 24 patients were hospitalized due to 
diabetic complications like, diabetic foot ulcer (n= 13), diabetic ketoacidosis (07), 
diabetic nephropathy (01), diabetic retinopathy (03). 5 patients were admitted due 
to diabetes induced renal failure. ConClusions: In conclusion, our study revealed 
that poor adherence leads hospitalization and increases the economic burden of 
diabetic patient. By conducting diabetes awareness camps and continued medica-
tion education programme through diabetic centers in village setup can significantly 
reduces the non adherences.
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objeCtives: Elderly population is growing and so is the prevalence of diabetes 
among them. The present study was to explore direct medical cost and medication 
usage pattern in hospitalized elderly patients with type 2 diabetes (T2D) among 
